{
  "name": "FDA warning letters naming GLP-1 and peptide sellers",
  "description": "Every FDA warning letter in the naming window that mentions a tracked GLP-1 drug or peptide. Each row keeps FDA’s subject line, both dates and close-out status.",
  "author": "HealthspanLedger",
  "edition": "2026.08",
  "version": "f72779015267",
  "page": "https://healthspanledger.com/access/enforcement",
  "citeAs": "HealthspanLedger. FDA warning letters naming GLP-1 and peptide sellers. Edition 2026.08 (version f72779015267). Derived from FDA warning letter index, US Food and Drug Administration, retrieved 2026-08-12. Licensed CC BY 4.0. https://healthspanledger.com/access/enforcement",
  "license": {
    "url": "https://creativecommons.org/licenses/by/4.0/",
    "name": "Creative Commons Attribution 4.0 International (CC BY 4.0)"
  },
  "source": {
    "name": "FDA warning letter index, US Food and Drug Administration",
    "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters",
    "retrieved": "2026-08-12",
    "publisherLastUpdated": null,
    "license": "https://www.usa.gov/publicdomain/label/1.0/",
    "licenseName": "US Government work, public domain"
  },
  "arrangement": "The underlying records are United States government work and carry no copyright. How this table selects, joins, labels and bounds them is ours, and that work is licensed CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/): reuse it, including commercially, and credit HealthspanLedger with a link to the page it came from.",
  "temporalCoverage": "2024-08-12/2026-08-12",
  "measurementTechnique": "Six full-text searches of FDA’s own warning-letter index. A term matches anywhere in a letter, so every match is read before it is published, and a letter is published only where its own FDA page answered HTTP 200 on the retrieval date.",
  "readThisFirst": [
    "A warning letter is an allegation, not a finding. FDA states its own view; a court has decided nothing.",
    "An empty closeout_date is not 'still open'. Close-out is a process a company has to ask for, and many resolved matters never get one.",
    "A company absent from this table means nothing. It has not been checked and found clean.",
    "This file covers letters issued from 2024-08-12 onward, not FDA’s whole archive of 3,651 letters."
  ],
  "rows": [
    {
      "company": "Wholesale Peptide",
      "issue_date": "2026-06-17",
      "posted_date": "2026-06-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "peptide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026"
    },
    {
      "company": "Altru Telehealth, LLC dba Altru Telehealth",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/altru-telehealth-llc-dba-altru-telehealth-728274-06082026"
    },
    {
      "company": "Amie Health, Inc. dba Amie",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amie-health-inc-dba-amie-728276-06082026"
    },
    {
      "company": "Clover Meds LLC dba Clover Meds",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clover-meds-llc-dba-clover-meds-728234-06082026"
    },
    {
      "company": "D&H Medical Services",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dh-medical-services-728238-06082026"
    },
    {
      "company": "Eden Health International Inc. dba Eden",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eden-health-international-inc-dba-eden-728279-06082026"
    },
    {
      "company": "Ezra Holdco LLC dba Ezra",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ezra-holdco-llc-dba-ezra-730995-06082026"
    },
    {
      "company": "FITISH",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"
    },
    {
      "company": "FitRX, LLC dba AM RX",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-am-rx-728275-06082026"
    },
    {
      "company": "Glow Medispa, LLC dba Mint Med",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-medispa-llc-dba-mint-med-730390-06082026"
    },
    {
      "company": "HydraMed IV LLC dba HydraMed",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hydramed-iv-llc-dba-hydramed-728282-06082026"
    },
    {
      "company": "Joi and Blokes dba Joi + Blokes",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026"
    },
    {
      "company": "Maximus Health, Inc. dba Maximus",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026"
    },
    {
      "company": "Medica Weight Loss",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026"
    },
    {
      "company": "Momentum Health 360 dba Momentum Health",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026"
    },
    {
      "company": "NativeMed LLC dba NativeMed",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nativemed-llc-dba-nativemed-728287-06082026"
    },
    {
      "company": "Nexlife Inc. dba Nexlife",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexlife-inc-dba-nexlife-730096-06082026"
    },
    {
      "company": "Nexus Health Solutions LLC dba Harper Meds",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexus-health-solutions-llc-dba-harper-meds-728281-06082026"
    },
    {
      "company": "Nova Vascular LLC dba NOVARX",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nova-vascular-llc-dba-novarx-728290-06082026"
    },
    {
      "company": "OrderlyMeds LLC dba OrderlyMeds",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orderlymeds-llc-dba-orderlymeds-728291-06082026"
    },
    {
      "company": "Public Health Solution LLC dba DrMedHealth",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026"
    },
    {
      "company": "Ready Med",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026"
    },
    {
      "company": "Roen Health, Inc. dba RoenRx",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026"
    },
    {
      "company": "Thrivelab Co. dba Thrivelab",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrivelab-co-dba-thrivelab-728294-06082026"
    },
    {
      "company": "Trinity HealthCare Supply, LLC dba altRx",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026"
    },
    {
      "company": "VivioMD Group LLC dba VivioMD",
      "issue_date": "2026-06-08",
      "posted_date": "2026-06-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viviomd-group-llc-dba-viviomd-728295-06082026"
    },
    {
      "company": "Harbin Jixianglong Biotech Co., Ltd.",
      "issue_date": "2026-05-01",
      "posted_date": "2026-05-19",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "CGMP/API/Adulterated and Misbranded Drugs",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026"
    },
    {
      "company": "New Life Pharma LLC",
      "issue_date": "2026-04-14",
      "posted_date": "2026-04-21",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "CGMP/Adulterated and Unapproved New Drug/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-pharma-llc-725661-04142026"
    },
    {
      "company": "ProRx LLC",
      "issue_date": "2026-04-07",
      "posted_date": "2026-05-12",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026"
    },
    {
      "company": "FormPour",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "name:FormPour",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/formpour-722215-03312026"
    },
    {
      "company": "Gram Peptides",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; retatrutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"
    },
    {
      "company": "Guangzhou Huli Technology Co., Ltd. dba Fantasy Face",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026"
    },
    {
      "company": "Lovega LLC dba Pink Pony Peptides",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; retatrutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026"
    },
    {
      "company": "Mile High Compounds LLC",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026"
    },
    {
      "company": "PekCura Labs",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "cagrilintide; glp-1; peptide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026"
    },
    {
      "company": "Prime Sciences",
      "issue_date": "2026-03-31",
      "posted_date": "2026-04-07",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs Sold Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "cagrilintide; glp-1; peptide; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026"
    },
    {
      "company": "Novo Nordisk Inc.",
      "issue_date": "2026-03-05",
      "posted_date": "2026-03-10",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Postmarketing Adverse Drug Experience Reporting Requirements",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-717576-03052026"
    },
    {
      "company": "24HrDoc, Inc. dba 24HrDoc",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/24hrdoc-inc-dba-24hrdoc-717984-02202026"
    },
    {
      "company": "Alan Health Technologies Inc. dba Alan",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alan-health-technologies-inc-dba-alan-721814-02202026"
    },
    {
      "company": "Aspen Aesthetics dba Fifty 410",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-aesthetics-dba-fifty-410-721481-02202026"
    },
    {
      "company": "Belle Health LLC dba Belle",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/belle-health-llc-dba-belle-721795-02202026"
    },
    {
      "company": "Better Health Labs, Inc. dba Measured",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/better-health-labs-inc-dba-measured-721454-02202026"
    },
    {
      "company": "Bliv Wellness LLC dba Bliv",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bliv-wellness-llc-dba-bliv-721479-02202026"
    },
    {
      "company": "BluefitMD",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bluefitmd-721446-02202026"
    },
    {
      "company": "Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/deluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026"
    },
    {
      "company": "Dripgym Mobile Parent, LLC dba Amp Health",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dripgym-mobile-parent-llc-dba-amp-health-717992-02202026"
    },
    {
      "company": "FitRX, LLC dba FitRx",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-fitrx-717987-02202026"
    },
    {
      "company": "Genesis Health International Inc. dba Genesis",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genesis-health-international-inc-dba-genesis-721451-02202026"
    },
    {
      "company": "Good Girl LLC dba GoodGirlRX",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/good-girl-llc-dba-goodgirlrx-721449-02202026"
    },
    {
      "company": "Ivim Services LLC dba Ivim",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivim-services-llc-dba-ivim-721816-02202026"
    },
    {
      "company": "Join Josie",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/join-josie-717986-02202026"
    },
    {
      "company": "Kare Solutions, LLC dba Zappy",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kare-solutions-llc-dba-zappy-717991-02202026"
    },
    {
      "company": "Kin Meds",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026"
    },
    {
      "company": "Lean Rx, Inc. dba SkinnyRx",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026"
    },
    {
      "company": "Levity Inc. dba Levity",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"
    },
    {
      "company": "MaxLife Technologies Inc. dba Maxlife",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maxlife-technologies-inc-dba-maxlife-721453-02202026"
    },
    {
      "company": "MEDVi, LLC dba MEDVi",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026"
    },
    {
      "company": "Newman Clinic, PLLC dba Newman Clinic",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newman-clinic-pllc-dba-newman-clinic-721470-02202026"
    },
    {
      "company": "NewSelf Limited dba NewSelf",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newself-limited-dba-newself-721472-02202026"
    },
    {
      "company": "Peaks Curative, LLC dba Peaks",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peaks-curative-llc-dba-peaks-721817-02202026"
    },
    {
      "company": "PharmaZee",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmazee-721473-02202026"
    },
    {
      "company": "Premium Health Management Inc. dba Premium Health",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-05",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026"
    },
    {
      "company": "Refills Health, LLC dba Refills Health",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/refills-health-llc-dba-refills-health-721475-02202026"
    },
    {
      "company": "Strut Health, LLC dba Strut",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026"
    },
    {
      "company": "Viv Health, Inc. dba VIV RX",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viv-health-inc-dba-viv-rx-721818-02202026"
    },
    {
      "company": "Weightless Medical LLC dba WeightCare",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/weightless-medical-llc-dba-weightcare-721478-02202026"
    },
    {
      "company": "Zeuss LLC dba Zeuss",
      "issue_date": "2026-02-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zeuss-llc-dba-zeuss-717985-02202026"
    },
    {
      "company": "Thrive Health and Wellness, LLC dba Thrive Health Solutions",
      "issue_date": "2026-02-09",
      "posted_date": "2026-04-21",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": "2026-08-06",
      "matched_search_terms": "tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026"
    },
    {
      "company": "GenoGenix LLC",
      "issue_date": "2026-01-20",
      "posted_date": "2026-03-03",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026"
    },
    {
      "company": "Boothwyn Pharmacy, LLC",
      "issue_date": "2026-01-16",
      "posted_date": "2026-02-10",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026"
    },
    {
      "company": "Pinnacle Professional Research dba Pinnacle Peptides",
      "issue_date": "2025-12-12",
      "posted_date": "2025-12-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "peptide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025"
    },
    {
      "company": "Darmerica, LLC",
      "issue_date": "2025-12-08",
      "posted_date": "2025-12-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "cagrilintide; glp-1; peptide; retatrutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025"
    },
    {
      "company": "Apothecary Pharma, LLC",
      "issue_date": "2025-12-01",
      "posted_date": "2026-03-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025"
    },
    {
      "company": "PQ Pharmacy, LLC",
      "issue_date": "2025-10-10",
      "posted_date": "2025-12-02",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pq-pharmacy-llc-715795-10102025"
    },
    {
      "company": "Chengdu Brilliant Biopharmaceutical Co., Ltd.",
      "issue_date": "2025-09-11",
      "posted_date": "2025-09-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "CGMP/Finished Pharmaceuticals/Adulterated",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025"
    },
    {
      "company": "motionpharmacy.com",
      "issue_date": "2025-09-10",
      "posted_date": "2025-09-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drug/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/motionpharmacycom-715595-09102025"
    },
    {
      "company": "All American Wellness",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-american-wellness-715991-09092025"
    },
    {
      "company": "Amazing Meds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "retatrutide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazing-meds-715506-09092025"
    },
    {
      "company": "ASN-LABS",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "retatrutide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025"
    },
    {
      "company": "Bioverse, Inc. dba Bioverse",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bioverse-inc-dba-bioverse-716508-09092025"
    },
    {
      "company": "Body Good Studio",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/body-good-studio-716460-09092025"
    },
    {
      "company": "Canada Med Stop",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/canada-med-stop-716517-09092025"
    },
    {
      "company": "Cosmo Medical Spa dba Cosmo Med Spa",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025"
    },
    {
      "company": "Curex",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curex-716821-09092025"
    },
    {
      "company": "directmeds.com, Inc. dba DirectMeds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025"
    },
    {
      "company": "Dr. Gater's Weight Loss & Wellness",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-gaters-weight-loss-wellness-712866-09092025"
    },
    {
      "company": "EA WORKS Limited Liability Company dba Trust Labs",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ea-works-limited-liability-company-dba-trust-labs-715798-09092025"
    },
    {
      "company": "eDrugstore",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025"
    },
    {
      "company": "Elevate Your Wellness LLC, dba Elevated",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elevate-your-wellness-llc-dba-elevated-719811-09092025"
    },
    {
      "company": "Eli Lilly and Company",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716485-09092025"
    },
    {
      "company": "Eli Lilly and Company",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716462-09092025"
    },
    {
      "company": "Eli Lilly and Company",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716475-09092025"
    },
    {
      "company": "Elite Health Center",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elite-health-center-715869-09092025"
    },
    {
      "company": "EvoLife Wellness",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolife-wellness-715507-09092025"
    },
    {
      "company": "Expert Aesthetics",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/expert-aesthetics-715796-09092025"
    },
    {
      "company": "Fancy Meds, LLC dba Fancy Meds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancy-meds-llc-dba-fancy-meds-716487-09092025"
    },
    {
      "company": "FitRX, LLC dba Zealthy",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-zealthy-716501-09092025"
    },
    {
      "company": "FWD Care, Inc. dba FWD",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fwd-care-inc-dba-fwd-716696-09092025"
    },
    {
      "company": "GenLabMeds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"
    },
    {
      "company": "Get.Fit.Medical, LLC dba Get.Fit.Medical",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/getfitmedical-llc-dba-getfitmedical-715801-09092025"
    },
    {
      "company": "GLP-1 Solution",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025"
    },
    {
      "company": "HealBerry",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healberry-719809-09092025"
    },
    {
      "company": "Healthon Inc. dba Healthon",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthon-inc-dba-healthon-719809-09092025"
    },
    {
      "company": "Healthy Living Clinic",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-living-clinic-09092025"
    },
    {
      "company": "Healthy Male",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-male-716506-09092025"
    },
    {
      "company": "Hims & Hers Health, Inc. dba Hers",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025"
    },
    {
      "company": "Hims & Hers Health, Inc. dba Hims",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025"
    },
    {
      "company": "inspire.clinic",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inspireclinic-715799-09092025"
    },
    {
      "company": "Intimate Rose",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intimate-rose-716458-09092025"
    },
    {
      "company": "Invigorate Med Spa",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invigorate-med-spa-715872-09092025"
    },
    {
      "company": "iVisitDoc, Inc. dba iVisitDoc",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivisitdoc-inc-dba-ivisitdoc-716826-09092025"
    },
    {
      "company": "JulyMD",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/julymd-716828-09092025"
    },
    {
      "company": "Las Villas Health Care LLC dba Villas Health",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/las-villas-health-care-llc-dba-villas-health-716504-09092025"
    },
    {
      "company": "Lean Dreams LLC dba LeanDreams",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-dreams-llc-dba-leandreams-716697-09092025"
    },
    {
      "company": "Lovely Meds, Inc. dba Lovely Meds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovely-meds-inc-dba-lovely-meds-716829-09092025"
    },
    {
      "company": "Lumimeds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lumimeds-716510-09092025"
    },
    {
      "company": "Lyfe Rx",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lyfe-rx-09092025"
    },
    {
      "company": "Mane & Steel, LLC. dba Mane & Steel",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mane-steel-llc-dba-mane-steel-716455-09092025"
    },
    {
      "company": "Master Pharmaceuticals Group",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/master-pharmaceuticals-group-715800-09092025"
    },
    {
      "company": "Matthew Stern, CEO MyStart Health LLC.",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/matthew-stern-ceo-mystart-health-llc-714755-09092025"
    },
    {
      "company": "MedClub by Dr. Jenn",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "retatrutide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025"
    },
    {
      "company": "Novo Nordisk Inc.",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "False & Misleading Claims/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025"
    },
    {
      "company": "Nuvo Life Health Inc. dba Nuvo Life Health",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuvo-life-health-inc-dba-nuvo-life-health-715794-09092025"
    },
    {
      "company": "Remedy Meds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedy-meds-716830-09092025"
    },
    {
      "company": "Reset IV, LLC dba Reset IV",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reset-iv-llc-dba-reset-iv-716488-09092025"
    },
    {
      "company": "SemaBio",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/semabio-715866-09092025"
    },
    {
      "company": "SimpleRx",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/simplerx-715874-09092025"
    },
    {
      "company": "Slendid",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025"
    },
    {
      "company": "Sprout Health Partners LLC dba Sprout Health",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sprout-health-partners-llc-dba-sprout-health-715879-09092025"
    },
    {
      "company": "The HCG Institute",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hcg-institute-716512-09092025"
    },
    {
      "company": "Try Nova",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/try-nova-716695-09092025"
    },
    {
      "company": "TRYM Health, Inc. dba TRYM Health",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trym-health-inc-dba-trym-health-716699-09092025"
    },
    {
      "company": "Tuyo Health, Inc. dba Tuyo Health",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tuyo-health-inc-dba-tuyo-health-716502-09092025"
    },
    {
      "company": "Vitals RX",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitals-rx-715868-09092025"
    },
    {
      "company": "ybycmeds",
      "issue_date": "2025-09-09",
      "posted_date": "2025-09-16",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "peptide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ybycmeds-715878-09092025"
    },
    {
      "company": "cheaptrustedpharmacy.com",
      "issue_date": "2025-07-29",
      "posted_date": "2025-09-23",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheaptrustedpharmacycom-705501-07292025"
    },
    {
      "company": "www.buynetmeds.com",
      "issue_date": "2025-06-12",
      "posted_date": "2025-07-01",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwbuynetmedscom-706335-06122025"
    },
    {
      "company": "www.peacefulmeds.com",
      "issue_date": "2025-05-05",
      "posted_date": "2025-06-24",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwpeacefulmedscom-703470-05052025"
    },
    {
      "company": "www.24hreup.biz",
      "issue_date": "2025-04-23",
      "posted_date": "2025-06-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/www24hreupbiz-700358-04232025"
    },
    {
      "company": "Tailstorm Health Inc. dba Medivant Health",
      "issue_date": "2025-04-08",
      "posted_date": "2025-05-13",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": "2026-04-14",
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailstorm-health-inc-dba-medivant-health-703497-04082025"
    },
    {
      "company": "ProRx, LLC",
      "issue_date": "2025-03-04",
      "posted_date": "2025-03-04",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Compounding Pharmacy/Adulterated Drug Products",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025"
    },
    {
      "company": "USApeptide.com",
      "issue_date": "2025-02-26",
      "posted_date": "2025-03-11",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025"
    },
    {
      "company": "www.weightcrunchshop.com",
      "issue_date": "2025-01-13",
      "posted_date": "2025-01-21",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwweightcrunchshopcom-695815-01132025"
    },
    {
      "company": "Prime Vitality, Inc. dba Prime Peptides",
      "issue_date": "2024-12-10",
      "posted_date": "2024-12-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"
    },
    {
      "company": "Summit Research Peptides",
      "issue_date": "2024-12-10",
      "posted_date": "2024-12-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "cagrilintide; glp-1; peptide; retatrutide; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024"
    },
    {
      "company": "Swisschems",
      "issue_date": "2024-12-10",
      "posted_date": "2024-12-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; peptide; retatrutide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024"
    },
    {
      "company": "Veronvy",
      "issue_date": "2024-12-10",
      "posted_date": "2024-12-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/veronvy-694688-12102024"
    },
    {
      "company": "Xcel Research LLC",
      "issue_date": "2024-12-10",
      "posted_date": "2024-12-17",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "cagrilintide; glp-1; peptide; retatrutide; semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024"
    },
    {
      "company": "Nomida.biz",
      "issue_date": "2024-09-12",
      "posted_date": "2024-09-24",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Unapproved New Drugs/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "glp-1; semaglutide; tirzepatide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nomidabiz-687590-09122024"
    },
    {
      "company": "AnuMed International, LLC",
      "issue_date": "2024-08-20",
      "posted_date": "2024-08-27",
      "issuing_office": "Center for Drug Evaluation and Research (CDER)",
      "subject": "Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded",
      "response_date": null,
      "closeout_date": null,
      "matched_search_terms": "semaglutide",
      "letter_url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anumed-international-llc-674310-08202024"
    }
  ]
}